- Previous Close
509.03 - Open
514.76 - Bid 510.48 x 100
- Ask 511.95 x 100
- Day's Range
509.47 - 518.91 - 52 Week Range
372.50 - 583.39 - Volume
276,330 - Avg. Volume
461,931 - Market Cap (intraday)
42.123B - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
50.77 - EPS (TTM)
10.08 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
531.19
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
www.idexx.com11,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IDXX
View MorePerformance Overview: IDXX
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IDXX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IDXX
View MoreValuation Measures
Market Cap
42.12B
Enterprise Value
42.79B
Trailing P/E
50.77
Forward P/E
45.25
PEG Ratio (5yr expected)
5.39
Price/Sales (ttm)
11.34
Price/Book (mrq)
26.66
Enterprise Value/Revenue
11.31
Enterprise Value/EBITDA
35.16
Financial Highlights
Profitability and Income Statement
Profit Margin
22.34%
Return on Assets (ttm)
22.77%
Return on Equity (ttm)
63.25%
Revenue (ttm)
3.78B
Net Income Avi to Common (ttm)
845.63M
Diluted EPS (ttm)
10.08
Balance Sheet and Cash Flow
Total Cash (mrq)
401.59M
Total Debt/Equity (mrq)
67.58%
Levered Free Cash Flow (ttm)
816.01M
Research Analysis: IDXX
View MoreCompany Insights: IDXX
IDXX does not have Company Insights
Research Reports: IDXX
View MoreIdexx Labs: As Top Dog in Pet Diagnostics, Idexx Has Dug a Wide Moat
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
RatingPrice TargetRaising target price to $538.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $538.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $521.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $521.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $507.00
IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $507.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target